The frequency of CCND1 amplification and FANCA loss was higher in TPBCs than in ER-PR-HER2+ breast cancers (CCND1: 26% vs. 6%, P = 0.013; FANCA, 72% vs. 50%, P = 0.023). This evidence concerns the gene ESR1 and breast carcinoma.